Moderna's Best Day Ever Turned Into a Whiplash Lesson for Options Traders Chasing the Squeeze

The best trading day in Moderna's history

On August 19, 2026, Moderna's stock closed at $174.38, up roughly 177% from the prior day's $62.96 close. It was the single best trading day the company has ever had, on volume of about 185 million shares — more than 18 times normal.

The trigger was real news, not speculation. Merck and Moderna announced that their Phase 3 trial (called INTerpath-001) of an experimental melanoma vaccine met its main goal. The trial tested intismeran autogene — a personalized mRNA cancer vaccine built from a patient's own tumor mutations — combined with Merck's Keytruda, against Keytruda alone, in 1,137 patients with resected (surgically removed) Stage IIB-IV melanoma.

The companies' announcement didn't disclose specific percentage or hazard-ratio figures (a standard measure of risk reduction) for this Phase 3 result itself — they described it as a "statistically significant and clinically meaningful" improvement in both measures versus Keytruda alone, with full data to be presented at a future medical meeting. What they did point to is the earlier, smaller study that led to this trial: a Phase 2b study of the same combination (the KEYNOTE-942 trial, five-year follow-up data presented at the 2026 ASCO Annual Meeting) had shown a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis, versus Keytruda alone. That earlier result is why this Phase 3 confirmatory trial was so closely watched — it's context for the stakes, not a restatement of the new trial's own numbers, which haven't been fully disclosed yet. Even without the specific figures, it's described as the first positive Phase 3 result for an individualized mRNA-based cancer therapy — a genuine scientific milestone, not just a stock story. Merck's own shares rose more than 12% the same day.

Phase 3 is the last stage of clinical testing before a drug can typically be submitted to regulators for approval — a positive Phase 3 result is a strong signal, but it isn't the same thing as FDA approval, which is a separate, later step.

Why the move was this violent: a short squeeze

A 177% one-day move in a large, widely followed biotech is unusual even for great trial news. Part of what made it this extreme was Moderna's short interest — the percentage of a stock's available shares that traders have borrowed and sold, betting the price will fall. Going into the announcement, roughly 13.5% of Moderna's freely traded shares were sold short, a notably high level for a large-cap stock.

When the trial news hit and the stock started climbing, short sellers who had bet against Moderna faced mounting losses on paper. Some were forced to buy shares to close out their bets and cap the damage — and that buying pressure pushes the price up further, which forces more short sellers to buy, in a feedback loop known as a short squeeze. Estimates of how much money short sellers lost that day range from about $4.8 billion to $5.5 billion, depending on the source and exact timing of the calculation — a reminder that these figures are estimates built from imperfect real-time data, not audited totals.

One technical gauge captured just how stretched the move had become: Moderna's Relative Strength Index (RSI), a 0-100 scale that measures how fast and how far a stock has moved recently, reportedly hit about 92 — the highest reading in the stock's history. Readings above 70 are conventionally considered "overbought," meaning the move has been unusually fast relative to its own recent history, not that a pullback is guaranteed.

The whiplash: giving a chunk of it back

This is the part that matters most for anyone thinking about buying options into a move like this. Moderna didn't just rally and hold — it round-tripped hard. The next session, the stock fell somewhere in the range of roughly 20% to 25% from Wednesday's close (reports vary by exact timing), before climbing back about 9% the following day.

That sequence — up 177%, down roughly a fifth to a quarter, up high single digits — is a textbook illustration of mean reversion risk: after an unusually large, fast move, prices often give back some of the gain as the most reactive buyers and short-covering pressure fade, even when the underlying news was genuinely positive.

The options lesson: the news is already in the price

Here's the trap retail traders commonly fall into after a move like this: seeing a huge rally, feeling like they missed it, and buying call options the next morning to try to catch the continuation. The problem is that options premiums are priced using implied volatility (IV) — the market's estimate of how much a stock is likely to swing before the option expires. After a shock like Moderna's, IV on its options doesn't just stay elevated; it often spikes dramatically, because the market now expects that more big moves are possible.

Buying an option when IV is already sky-high means paying a much richer premium than in the week before. And if a stock merely goes sideways, or drifts down the way Moderna did the very next day, that elevated IV tends to collapse (a pattern often called "IV crush") — which can erode an option's value even if the stock doesn't move against the position much at all. Someone who bought calls at Wednesday's close and watched Thursday's pullback could have lost a meaningful share of that premium to IV collapse, on top of the price move itself. And it's worth remembering that a long option carries no floor: if it expires out-of-the-money, the entire premium paid is lost, with no assignment or partial-recovery mechanism involved.

None of this means the trade never works — sometimes a stock keeps running. But it's a fundamentally different, higher-risk bet than buying options before a catalyst, because it means paying peak price for volatility that has already partly played out. Some traders who still want exposure after a move like this use defined-risk structures, like vertical spreads (buying one option and selling another at a different strike). That structure caps the maximum possible loss at the net premium paid, and it reduces — though doesn't eliminate — sensitivity to an IV collapse compared with a single long call. That cap on loss comes with a trade-off, though: a vertical spread also caps the maximum possible gain, and the premium paid for it can still be lost in full if the trade doesn't work out. Options trading carries substantial risk, including total loss of the premium paid, and isn't suitable for every investor or every account.

The takeaway

A single positive trial result, even a strong one, doesn't guarantee a drug reaches approval, launches successfully, or ever generates the revenue a 177% stock move might seem to be pricing in — later trial stages, regulatory review, and commercial execution all remain ahead. And for options traders specifically, a stock's most newsworthy day is often the most expensive day to bet on more of the same move, precisely because everyone else is trying to do it too.

This article is educational commentary on public market events, not personalized investment, trading, or tax advice.